SP
Spero Therapeutics, Inc.
SPRO · NASDAQ
$1.17 -2.50% (-$0.03)
1M -4.88%
Market Cap $67.7M
P/E Ratio 9.18x
Div. Yield -
ROE 16.17%
Piotroski F-Score Moderate
6/9Valuation
99 /100
Cheap P/E 9.18x
P/B 1.53x
EV/EBITDA 2.47x
Growth
42 /100
Stable Rev. growth 7.06%
Book val. growth 8.06%
EPS growth N/A
Profitability
87 /100
Strong Gross margin 100.00%
FCF margin 45.57%
Net margin 17.18%
Quality
75 /100
Excellent ROIC 12.56%
Asset turnover 0.81x
ROE 16.17%
Debt
100 /100
Low Debt/Equity 0.05x
Net debt/EBITDA -6.33x
Current ratio 6.12x
Stability
12 /100
Unstable Beta 1.48x
Profitable years 1
Rev. volatility 83.77%
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre SPRO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Esther Rajavelu
Employees
25
Headquarters
Cambridge
Evenimente viitoare
12 NOV.
Earnings
Upcoming earnings report